Research by Sang et al. revealed that the heightened expression level of METTL3 and METTL14 correlates with decreased AML patient survival and identifies the oncogenic potential of METTL3 and METTL14 in AML through the MDM2/p53 signaling axis (51). The gene discussed is TP53; the disease is acute myeloid leukemia.